Britannia Life Sciences Inc.
BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 268.96% | -60.46% | -- | 65.91% | 7.42% |
| Total Depreciation and Amortization | -1.77% | 5.61% | -- | 4.55% | 5.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,747.08% | 87.23% | -- | -112.48% | -83.33% |
| Change in Net Operating Assets | 15.44% | -1,461.08% | -- | -98.51% | -346.46% |
| Cash from Operations | 54.94% | 86.01% | -- | -678.33% | -10,946.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4,400.89% | -100.00% | -- | -5,184.13% | -186.83% |
| Cash from Investing | 4,400.89% | -100.00% | -- | -5,184.13% | -186.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 17.45% | 97.63% | -- | -28.94% | -41.23% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 475.93% | 90.37% | -- | -115.54% | 94.32% |
| Foreign Exchange rate Adjustments | 365.12% | 112.24% | -- | -89.79% | -145.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 698.17% | -107.41% | -- | -2,440.59% | -191.77% |